Drug
Miglustat clinical trials
Also written Zavesca, OGT 918 and Butyldeoxynojirimycin.
- studies test it
- 22
- open now
- 1
- in phase 3
- 7
- first study started
- 2002
Keep track of what changes. Save the miglustat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2002 (3)
| Year | Studies |
|---|---|
| 2002 | 3 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- Phase 3
- 7
- Phase 4
- 3
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 12
Actelion (5) · Amicus Therapeutics (3) · National Taiwan University Hospital (2) · G D Searle (2) · IRCCS Fondazione Stella Maris (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · National Eye Institute (NEI) (1) · The Hospital for Sick Children (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses miglustat is read from its arms, and is right about nine times in ten.
Testing it · 22
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18RecruitingPhase 3Amicus TherapeuticsNCT04808505Written as Miglustat
- ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDActive, not recruitingPhase 3Amicus TherapeuticsNCT03911505Written as Miglustat
- Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD)TerminatedPhase 3Tehran University of Medical SciencesNCT03822013Written as Miglustat
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseaseCompletedPhase 3Amicus TherapeuticsNCT03729362Written as Miglustat
- Safety and Efficacy of Miglustat in Chinese NPC PatientsCompletedPhase 4ActelionNCT03910621Written as Miglustat
- Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher DiseaseCompletedPhase 3ActelionNCT00319046Written as Miglustat
- Miglustat in Niemann-Pick Type C DiseaseCompletedPhase 2ActelionNCT00517153Written as miglustat
- Testing Miglustat Administration in Subjects With Spastic Paraplegia 11CompletedPhase 2IRCCS Fondazione Stella MarisNCT04768166Written as Miglustat 100 MG
- Synergistic Enteral Regimen for Treatment of the GangliosidosesTerminatedPhase 4University of MinnesotaNCT02030015Written as miglustat
- Miglustat on Gaucher Disease Type IIIBStatus unknownNot applicableNational Taiwan University HospitalNCT02520934Written as Miglustat
- A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated ReactionTerminatedPhase 1University of FloridaNCT02185651Written as Zavesca® Prescription
- OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher DiseaseCompletedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT00041535Written as OGT 918
- Saccadic Eye Movements in Patients With Niemann-Pick Type C DiseaseCompletedPhase 1National Eye Institute (NEI)NCT00316498Written as OGT918
- Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 GangliosidosisCompletedPhase 2The Hospital for Sick ChildrenNCT00418847Written as miglustat
- Miglustat in Cystic FibrosisCompletedPhase 2ActelionNCT00742092Written as miglustat
- Application of Miglustat in Patients With Niemann-Pick Type CCompletedPhase 3National Taiwan University HospitalNCT01760564Written as Miglustat
- Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?CompletedPhase 2Cliniques universitaires Saint-Luc- Université Catholique de LouvainNCT00945347Written as Miglustat
- Miglustat / OGT 918 in the Treatment of Cystic FibrosisTerminatedPhase 2ActelionNCT00537602Written as miglustat
- Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)CompletedPhase 4University of WashingtonNCT00194649Written as Miglustat (Zavesca)
- Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral DosesCompletedPhase 3Children's National Research InstituteNCT00672022Written as Zavesca (Miglustat)
Codes
What other systems call miglustat · ClinicalTrials.gg INT003439
- MeSH (NLM) C059896miglustatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ADN3S497AZMIGLUSTATConfirmed FDA, NLM, Wikidata
- RxNorm 402316Confirmed FDA, Wikidata
- Wikidata Q425911miglustatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1222MiglustatOne source FDA
- DrugBank DB00419One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C059896 | miglustat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ADN3S497AZ | MIGLUSTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 402316 | — | Confirmed FDA, Wikidata |
| Wikidata | Q425911 | miglustat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1222 | Miglustat | One source FDA |
| DrugBank | DB00419 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.